KENYA—Revital Healthcare EPZ Ltd. has announced several recent ground-breaking achievements that further reinforce its position as a pioneer in Africa’s healthcare industry.
This Kenyan company has become the first in East and Central Africa to manufacture essential medical devices, including auto-disabled syringes, ushering in a new era of African medical device production.
The global medical devices market, valued at US$512.29 billion in 2022, is projected to reach US$799.67 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 5.9%, according to Fortune Business Insights.
Revital’s AD syringe 0.5 ml stands out as the first and only one made in Africa, a noteworthy distinction considering other producers with WHO Prequalification (PQ) certification are located outside the continent.
The Kenyan government’s proactive approach, exempting various medical equipment and apparatus from VAT under the 2022/2023 budget, has further fueled investment in the health sector.
Notable exemptions include plant and machinery used in pharmaceutical manufacturing, medical oxygen supply to registered hospitals, and various medical consumables. Fitch Solutions predicts double-digit annual growth in the medical device market between 2019 and 2024.
Revital’s achievement of WHO PQ certification for its early activation auto-disable (AD) syringe in Africa on July 11, 2023, exemplifies the company’s decade-long commitment to injectable safety in Africa’s immunization programs.
This certification underscores Revital’s dedication to improving healthcare outcomes and achieving global health equity.
The company’s strategic collaboration with Mitsui O.S.K. Lines (MOL), formalized through a Memorandum of Understanding (MoU) on November 30th, aims to bolster healthcare kit production in Kenya.
This alliance addresses the increasing demand for critical healthcare products in Africa and beyond, aligning with reports from Fitch and the World Bank highlighting Kenya’s promising market for medical devices.
Revital Healthcare is not just breaking ground locally but has also achieved global recognition. With an exceptional eighth WHO Prequalification of Medicines Products (PQS) certification, it solidifies its status as the African manufacturer with the most qualifications.
Additionally, becoming the first in East and Central Africa to acquire US-FDA certification for its 0.5-ml Early Activation Syringe positions the company as a key player in the global healthcare landscape.
During the COVID-19 pandemic in 2021, Revital Healthcare’s impact reverberated globally as it secured a contract with UNICEF India to supply 50 million pieces of 2ml vaccine syringes, addressing a shortage in the South Asian country.
In partnership with USAID Kenya, Revital is embarking on a significant initiative to develop Africa’s largest Rapid Diagnostic Test Kits factory.
This facility, slated to produce 20 million test kits monthly, spans infectious and noncommunicable diseases, drugs of abuse, and animal testing.
This move aligns with the company’s commitment to making diagnostics more accessible and affordable, empowering individuals to take charge of their health.